Ying Huang
Stock Analyst at B of A Securities
(1.47)
# 1,459
Out of 4,653 analysts
37
Total ratings
55.56%
Success rate
8.15%
Average return
Main Sectors:
Stocks Rated by Ying Huang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $550 → $541 | $483.96 | +11.79% | 10 | Oct 14, 2024 | |
| GILD Gilead Sciences | Maintains: Neutral | $70 → $72 | $92.11 | -21.83% | 8 | Feb 5, 2020 | |
| RDUS Radius Recycling | Maintains: Buy | $51 → $47 | $17.35 | +170.89% | 1 | Jul 25, 2018 | |
| RGNX REGENXBIO | Downgrades: Neutral | $64 → $80 | $11.14 | +618.13% | 3 | Jul 23, 2018 | |
| ESPR Esperion Therapeutics | Downgrades: Underperform | n/a | $2.10 | - | 2 | May 2, 2018 | |
| CTMX CytomX Therapeutics | Maintains: Buy | $34 → $40 | $1.00 | +3,900.00% | 2 | Mar 8, 2018 | |
| BLUE bluebird bio | Maintains: Neutral | $185 → $218 | $0.36 | +60,021.35% | 1 | Feb 22, 2018 | |
| PBYI Puma Biotechnology | Maintains: Buy | $135 → $115 | $2.99 | +3,746.15% | 2 | Jan 24, 2018 | |
| IRWD Ironwood Pharmaceuticals | Downgrades: Underperform | n/a | $4.11 | - | 4 | Jan 5, 2018 | |
| BIIB Biogen | Maintains: Buy | $358 → $365 | $164.89 | +121.36% | 1 | Oct 18, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $33 | $3.24 | +918.52% | 1 | Sep 22, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $380 | $3.31 | +11,380.36% | 1 | Jul 24, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $295.93 | - | 1 | Feb 1, 2017 |
Vertex Pharmaceuticals
Oct 14, 2024
Maintains: Buy
Price Target: $550 → $541
Current: $483.96
Upside: +11.79%
Gilead Sciences
Feb 5, 2020
Maintains: Neutral
Price Target: $70 → $72
Current: $92.11
Upside: -21.83%
Radius Recycling
Jul 25, 2018
Maintains: Buy
Price Target: $51 → $47
Current: $17.35
Upside: +170.89%
REGENXBIO
Jul 23, 2018
Downgrades: Neutral
Price Target: $64 → $80
Current: $11.14
Upside: +618.13%
Esperion Therapeutics
May 2, 2018
Downgrades: Underperform
Price Target: n/a
Current: $2.10
Upside: -
CytomX Therapeutics
Mar 8, 2018
Maintains: Buy
Price Target: $34 → $40
Current: $1.00
Upside: +3,900.00%
bluebird bio
Feb 22, 2018
Maintains: Neutral
Price Target: $185 → $218
Current: $0.36
Upside: +60,021.35%
Puma Biotechnology
Jan 24, 2018
Maintains: Buy
Price Target: $135 → $115
Current: $2.99
Upside: +3,746.15%
Ironwood Pharmaceuticals
Jan 5, 2018
Downgrades: Underperform
Price Target: n/a
Current: $4.11
Upside: -
Biogen
Oct 18, 2017
Maintains: Buy
Price Target: $358 → $365
Current: $164.89
Upside: +121.36%
Sep 22, 2017
Maintains: Buy
Price Target: $23 → $33
Current: $3.24
Upside: +918.52%
Jul 24, 2017
Initiates: Buy
Price Target: $380
Current: $3.31
Upside: +11,380.36%
Feb 1, 2017
Upgrades: Buy
Price Target: n/a
Current: $295.93
Upside: -